COVID-19 – Coronavirus Information and Updates

Oral Mucositis in Newly Diagnosed Head and Neck Cancers


 

ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) – Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer

Study Summary

The purpose of the phase 3, clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the severity of radiation induced oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck.

Principal Investigator:

Phase

  • III

If you have any questions regarding this study or think that you or your loved one may be eligible, please feel free to contact:
Julianne Wilson, MSN @ 908-237-2330 ex 2.

Location
HUNTERDON HEMATOLOGY ONCOLOGY, LLC
2100 Wescott Drive
Flemington, NJ 08822
Phone: 908-264-1670
Fax: 908-788-6412
Office Hours

Get in touch

908-264-1670